Prostate-Specific Antigen (PSA) as a Surrogate End Point for Survival in Prostate Cancer Clinical Trials-Reference-Cited by-同舟云学术

Prostate-Specific Antigen (PSA) as a Surrogate End Point for Survival in Prostate Cancer Clinical Trials

Published:2008-01 Issue:1 Volume:53 Page:6-9
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Collette Laurence

Publisher

Elsevier BV

Subject

Urology

Reference12 articles.

1. Endpoints and United States Food and Drug Administration Approval of Oncology Drugs;Johnson;J Clin Oncol,2003

2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

3. The validation of surrogate endpoints in meta-analyses of randomized experiments;Buyse;Biostatistics,2000

4. Surrogate end point for prostate cancer specific mortality after radical prostatectomy or radiation therapy;D’Amico;J Natl Cancer Inst,2003

5. Can biochemical failure (ASTRO definition) be used as a surrogate endpoint for prostate cancer survival in phase III localized prostate cancer clinical trials? Analysis of RTOG protocol 92-02;Sandler;J Clin Oncol,2003

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1);Prostate Cancer and Prostatic Diseases;2022-01-25

2. Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT;Case Reports in Oncology;2021-03-22

3. Whole‐body diffusion‐weighted magnetic resonance imaging: Diagnosis and follow up of prostate cancer and beyond;International Journal of Urology;2021-03-06

4. Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide;Minerva Urologica e Nefrologica;2020-12

5. Treatment outcomes for patients with metastatic castrate‐resistant prostate cancer following docetaxel for hormone‐sensitive disease;Asia-Pacific Journal of Clinical Oncology;2020-09-24